Redcare Pharmacy Shares Under Pressure from Dual Challenges

Redcare Pharmacy NL0012044747

Redcare Pharmacy's stock is experiencing significant selling pressure, dropping to a new 52-week low of €58.05. The decline is driven by a dual challenge: a substantial bond repayment coming due and a downward revision of its price target by a major investment bank. Despite ongoing growth in its core business, investor sentiment is currently dominated by liquidity concerns and valuation adjustments.

Adding to the downward momentum, Barclays published a research note on January 16 that revised its outlook for the company. The British investment bank lowered its price target for Redcare Pharmacy from €130 to €110, representing a reduction of approximately 15%. While Barclays maintained its "Overweight" rating on the equity, suggesting it still sees upside potential, the market's reaction indicates investors are placing greater emphasis on the lowered target than the continued positive recommendation. This adjustment was part of a broader sector analysis of European internet and e-commerce companies, reflecting a shift in valuation benchmarks across the industry.

A Major Cash Outflow for Bond Repayment

A key factor pressuring the stock is a €64.5 million bond repayment obligation falling due. This payment stems from a convertible bond issued in 2021 with a maturity date of 2028. Bondholders have exercised their right to sell the bonds back to the company, demanding cash repayment instead of opting for conversion into shares—a clear signal that they are not betting on an equity conversion. Although Redcare Pharmacy proactively issued new convertible bonds in 2025 and initiated a buyback process to manage the situation, the immediate cash outflow from today's payment is noticeably impacting the company's liquidity position. For shareholders, the smooth handling of this obligation is crucial to maintaining creditworthiness, even as the funds leave the corporate treasury.

Strong Operational Performance Contrasts with Weak Share Price

The pressure on the stock price exists alongside apparently robust operational results. In early January, Redcare Pharmacy released preliminary figures for the fourth quarter of 2025, showing revenue advanced to €794 million, up from €675 million in the prior-year period. For the full 2025 fiscal year, the company achieved total revenue of €2.9 billion, representing growth of roughly 24%.

Despite this double-digit expansion, the equity has lost substantial value. This divergence highlights a current market focus on profitability metrics and free cash flow generation over pure top-line sales growth. Investors are signaling a desire to see margin improvement, not just continued expansion in scale.

Technical Picture Shows Breakdown

From a chart perspective, the share price has broken through key technical support levels. Trading at €58.05, it now sits at its lowest point in a year. The previous support level near €63.70 has failed to hold. The next potential area of technical support now lies just below the €60 mark.

The stock is currently trading below both its 20-day and 50-day moving averages, and high volatility persists. Previous support around €64.50 is now expected to act as a new resistance zone for any potential price recovery.